Teva Pharma (TEVA), Active Biotech Update on Safety of Laquinimod Phase 2 as RRMS Treatment
Tweet Send to a Friend
Teva Pharma (NYSE: TEVA) and Active Biotech announced new follow-up data evaluating the clinical safety of laquinimod in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
